In a dramatic move set to transform the weight loss and diabetes treatment landscape, pharmaceutical titan Eli Lilly has implemented a massive price reduction for its Mounjaro injection in the United Kingdom.
The cost of the drug, known generically as tirzepatide, has been slashed by nearly half for some dose strengths. This strategic price cut comes hot on the heels of a significant supply deal secured with the NHS for its sister drug, Wegovy, signalling a fierce battle for market dominance in the lucrative anti-obesity sector.
Details of the Price Reduction
The new pricing structure sees the cost of a four-week pre-filled pen pack plummet. The lower 2.5mg, 5mg, and 7.5mg doses have been reduced to £115, down from their previous price of £149. In an even steeper cut, the higher 10mg, 12.5mg, and 15mg doses will now cost £199, a substantial drop from the original £349.
This recalibration makes the higher-strength pens significantly more affordable and is expected to broaden access for patients across the UK.
A Competitive Market
Eli Lilly's aggressive pricing is widely seen as a direct challenge to Novo Nordisk, the maker of rival injections Ozempic and Wegovy. The competition between these two pharmaceutical giants is intensifying as they vie for a larger share of the rapidly expanding market for GLP-1 receptor agonist drugs.
These treatments have surged in popularity due to their proven efficacy not only in managing type 2 diabetes but also in promoting substantial weight loss.
Implications for Patients and the NHS
This price reduction is a potential game-changer for patient access. For those seeking private prescriptions, the out-of-pocket cost will be considerably lower. More importantly, it could pave the way for the NHS to consider Mounjaro for wider use within its services in the future, following its recent authorisation for weight management.
A spokesperson for Eli Lilly stated: "The list price of Mounjaro® (tirzepatide) in the UK has been revised. This price change applies to all doses and reflects our commitment to ensuring broader patient access to this important medicine."
This major price cut marks a pivotal moment, potentially bringing effective weight loss and diabetes treatments within reach for thousands more people in the UK.
